Osceola Capital, a lower middle-market private equity firm, has formed Revelation Pharma Corp. to pursue investments and partnerships across the pharmacy compounding market in partnership with industry professional Jacob Beckel.
Concurrent with the formation of Revelation, the company has completed the acquisition of Pensacola, Florida-based Everwell Specialty Pharmacy. The acquisition is expected to be followed closely by multiple add-ons. The pharmacies in scope function as 503A compounders, which prepare specially compounded medications. Osceola and Beckel have identified a pipeline of additional transactions. Revelation represents the eighth platform in Osceola Fund I, the firm’s flagship institutional fund.
Beckel said, “The 503A pharmacy compounding segment has been historically fragmented and presents a unique opportunity for consolidation. Cost of compliance is increasing, making it difficult for smaller service providers to operate efficiently. Our vision is to bring together many high quality compounders and build a best in class 503A compounding business that has a strong culture of collaboration, compliance, and innovation.”
Ben Moe, Managing Partner at Osceola said, “Osceola has had a long-standing relationship with Jacob Beckel and we are excited to have the opportunity to formally partner with him and the Revelation Pharma team on this investment. We believe there are significant organic and M&A opportunities for growth in this segment.”
McGuireWoods and Reed Smith acted as legal counsel to Osceola.